English (UK)
中文版Henry Xiong
Sinovant Sciences (http://www.sinovant.com) is an innovative biopharmaceutical company based in Shanghai, Beijing and Hong Kong. Sinovant was founded by Chinese scientists and physicians, including Chinese “Returnees”. Sinovant is uniquely positioned to bring cutting-edge global medical innovation to China, and transformative Chinese medical innovation to the world.
Sinovant has a diverse pipeline of 11 investigational products in development, among which 5 drug candidates are in phase III or beyond. Our products span over 6 therapeutic areas including oncology, infectious disease, urology / nephrology, gastrointestinal diseases, dermatology and rare diseases.
Sinovant
Senior BD DirectorMs. Rosa Xu
Chairman，Mr. Rongguang WU is also the founder of Hongxing Erke , which is one of the most famous sports brands in China. We focus on investing in innovative biotech companies and healthcare funds worldwide. We have an expert team and also seek license-in opportunity of innovative drugs to develop and commercialize in China.
· Investment Cases
Previously, we've invested over 100 million dollars, more than 10 projects worldwide, including VIR Biotechnology, Beijing Genomics institution, GMAX Bio and two Top 10 biomedical funds in America, etc..
· Investment Preference
We don’t have clear limits on the investment scale and the proportion of shares, usually $5 million to $20 million of a single investment. Companies in initial stage to growth stage are all in our consideration. We can lead, co-lead, or join a round that others are leading.
Website：www.hongxingerke.com
Hongxing Erke Investment Company
Investment ManagerMr. Adam Xu
Shanghai T&W Pharmaceutical Co., Ltd.
BD DirectorMr. Kenneth Xu
Genova Inc., a bio-pharma company dedicated in the innovation of better protein-drugs for viral diseases, cancer and auto-immune diseases. Novaferon ，the first novel protein drug of Genova, shows antiviral efficacy on viral clearance in a proof of concept randomized clinical trial and approved by Healthcare Canada and PMDA of Japan entering into phase 3 multinational centers clinical trial in last December. We are right looking for strategic parthership with big pharma. Contact: ctxu@genova.cn
Genova Inc
Vice President & Corporate SecretaryDr. Chuanbo Xu
Freenome, Inc.
Senior Director, Clinical DevelopmentJohn Xu
We have a very unique T-cell engager Bi-specific antibody platform.
Our COVID-19 neutralization antibody project is in phae 2 clinical tiral.
We have about 10 different Bi-specific projects in pre-clinical stage focusing on oncology, autoimmune and ophthomology.
We are looking for China partners to codevelop the Bi-specific antibodies.
We are also raising the capital to set up the CHina subsidiary.
You can add my wechat: elite8800
Abpro
SVPSiyuan Xu
VISEN Pharmaceuticals (VISEN) was formed by Ascendis Pharma A/S (Nasdaq: ASND) and an investor syndicate led by Vivo Capital (along with participation by Sofinnova Ventures), to develop and commercialize Ascendis Pharma’s endocrinology rare disease therapies in Greater China. The pipeline of VISEN covers pediatric endocrinology, adult endocrinology, and rare disease. VISEN management team has extensive experience in the development and commercialization of endocrine disease products in Greater China. VISEN has a deep understanding of unmet medical needs in Chinese patients and is actively expanding its pipeline through in-licensing and partnership.
Responsive Web Design powered by 